MESO / Mesoblast Ltd

as of 2026-02-10

Bias: MixedRisk: ElevatedMixed structure, RSI neutral, risk elevated

Last

16.78

1D +5.20% • 5D -2.39% • 1M -15.55%

Company

Mesoblast Ltd is an Australian biotechnology company specializing in regenerative medicine. Founded in 2004, it is engaged in the development of allogeneic cell therapies derived from its proprietary mesenchymal stem cells. The company targets conditions such as heart failure, chronic pain, and inflammatory diseases, utilizing its advanced technology to create treatments that can potentially improve patient outcomes. Mesoblast's products are designed to harness the body's natural healing processes, offering new solutions for patients with serious health challenges.

Mini chart (last 120 D1 closes)

2025-09-17 → 2026-02-09

+5.20%

-2.39%

-15.55%

Vol (20d)

65.8%

Weather meter

Overall39

Trend50

Volatility18

Sentiment50

Technicals

MA20

17.63

Below short-term trend

MA50

18.12

Below medium-term trend

MA200

—

RSI14

49.7

Neutral

What traders watch now

Support (MA50)

18.12

Resistance (MA200)

—

Key risk

Range / chop

Time horizon

2–10 trading days

Articles

Opinion • Analysis • News

Mesoblast's Stem Cell Soap Opera Gets Another Buy Rating: Because Hope Springs Eternal in Biotech Hell

OPINION • 2026-02-09 • 1 sources

In a move that's equal parts optimistic and eyebrow-raising, CCORF analyst Madeleine Williams sticks to her guns with a buy rating on Mesoblast Ltd. (MEOBF.US), bumping the price target up to $2.33. We dive into this with all the salt it deserves, roasting the biotech's bumpy ride while keeping it real—no diamond hands required.